Business Context and Reporting Period
This Form 8-K Current Report was filed by Viking Therapeutics, Inc. on September 21, 2018, regarding events occurring on September 20, 2018. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 9,500,000 shares of Common Stock.
- Public Offering Price: $18.50 per share.
- Underwriter Purchase Price: $17.39 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to an additional 1,425,000 shares within 30 days.
- Expected Gross Proceeds: Approximately $175.8 million (excluding over-allotment and before deducting underwriting discounts and expenses).
- Expected Closing Date: On or about September 25, 2018.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with William Blair & Company, L.L.C. as the representative. The offering is being made pursuant to a previously effective Form S-3 registration statement. The agreement includes customary representations, warranties, indemnification provisions, and termination clauses.
Guidance, Outlook, and Restrictions
- Lock-Up Agreements: Directors and executive officers have entered into lock-up agreements prohibiting the sale or transfer of securities until December 19, 2018, without prior written consent.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the anticipated closing and proceeds. The Company cautions that these are subject to risks, including the ability to satisfy closing conditions and market conditions.
- Use of Proceeds: The filing text does not specify the intended use of proceeds beyond the transaction details.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received, as the filing states the closing is "expected" on or about September 25, 2018.
- Confirm whether the underwriters exercised the 1,425,000 share over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific underwriting discounts and commissions to determine net proceeds.
- Check subsequent filings for the actual use of proceeds and any changes to the Company's capital structure.